
Technology Solutions For Life Sciences at the Point-of-Care

Corporate Presentation



Our Mission

At OptimizeRx — we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies.



Growth Leaders | Growth Drivers



20+ Leading Health Services and Financial Businesses

N



EXPERIENCE

Med Panel

Will Febbo Chief Executive Officer



Ed Stelmakh Chief Financial Officer / Chief Operations Officer

EXPERIENCE 30+

Healthcare IT,

Carelirst 📲 🕅

Master Data Mgmt

CHANGE WebMD

20+ Senior Financial

EXPERIENCE



Johnson Afohnson



Operations, Sales, and Growing Partner Networks

CCH[®]Tagetik prog∩os



Steve Silvestro Chief Commercial Officer



Todd Inman Chief Technology Officer



EXPERIENCE 20+

Legal Corporate and Business Compliance



Marion Odence-Ford General Counsel & Chief Compliance Officer

At-a-Glance

A leading provider of point-of-care technology solutions helping patients start and stay on therapy

Corporate Profile


- Re-Founded in 2016, **OptimizeRx** enables engagement between life sciences organizations, physicians and patients
- OptimizeRx powers drug maker brand awareness with physicians as well as patient treatment initiation, affordability and adherence efforts
- Our **technology platform** coupled with the nation's largest patient point-of-care **network** connects the majority of U.S. physicians and millions of patients
- The Company has grown to **~110** employees across the United States and Croatia

Stock Information

Stock Price (as of 5/10/23)	\$14.28	
Shares Outstanding fully diluted (as of 3/31/23)	~17.1M	
Market Cap (as of 5/10/23)	~\$244.6M	
Cash, Cash Equivalents ¹ (as of 3/31/23)	\$73.7M	
Total Debt	\$0.00	
NASDAQ Exchange listed under ticker (NASDAQ:OPRX)		

(1) Includes short-term investments


Pharma is Facing New Problems... and Some Old Ones...





(1) ZS's 2017 AccessMonitor and AffinityMonitor Findings. (2) Center for Disease Control, "Prescription Medication Adherence". (3) U.S Department of Veterans Affairs, "Twelve million patients misdiagnosed yearly in America". (4) RxBenefits, "Don't Ignore the Growing Specialty Medication Trends. (5) Tethered to the EHR: Primary Care Physician Workload Assessment Using EHR Event Log Data and Time-Motion Observations. (6) ASPE Office of Science & Data Policy, "Trends in Prescription Drug Spending, 2016-2021".


... and Providers and Patients Face Similar Issues Around Therapeutics





Large, Under Penetrated Market With Strong Secular Tailwinds Driven by Increased Pharma Advertising Spend on Digital Channels


Total U.S. Commercial Digital Spend is Approximately \$10bn



How Does OptimizeRx Solve the Problem?


Optimize Rx Life Sciences **Technology to Reach Customers** 20 Need access to **Prescriber and Patient** doctors at the point relevant touchpoints a day of care and patients with HCPs vs 6.4 / month API Connectivity to leading • to adhere to **Physicians** EHRs, fully integrated into therapy Need information physician clinical workflows about disease-40%+ specific relevant Al-Driven Digital Platform therapies and the • monthly script increases ability to access when using the platform these therapies in Real World Evidence **Patients** the clinical setting Need access to **Decision Support Engine** >10:1 ROI affordable and relevant therapies Independently verified, average on pharma-sponsored and engagement measurable ROI and impact enterprise programs with the provider to on commercial performance ensure adherence of customers

Staying Ahead of the Industry with Smart, Data-Driven Technology



Optimize Rx

OptimizeRx Point-of-Care Reach: Touchpoints with HCPs In All the Right Places



Integrated Engagement at Point-of-Care and Beyond

During Care Delivery, On Breaks, and At Home

Clinically relevant and contextual communications via the EHR






Clinicians and Data Scientists at OptimizeRx leverage patient journey milestones and physician engagement preferences to time communications RWD-AI extends engagement points with the same pool of prescribers outside the EHR to care-adjacent digital settings



Enabling Awareness, Access & Adherence

Through AI-Driven Omni-Channel Engagement



OPRX Positioned to Win

Operating the largest point-of-care (POC) communications network in the nation

Customer demand shift to enterprise digital POC solutions across multiple commercial budget areas

Scalable operating model to achieve \$100's MM in revenue with attractive bottom line

(((0)))

Deeply embedded customer base transitioning to a strategic partner and enterprise contracts

Deep expertise facilitating POC communications technology in a highly complex and well-regulated area of healthcare

Optimize **R**×

Source: https://www.pharmacychecker.com/askpc/pharma-marketing-research-development/#!

Deeply Embedded Customer Base

Supporting 90% of all top Pharma Manufacturers




Driving long term, sustained marketing return on investment

Growing Presence Within Top Drugs

OptimizeRx has significant room to continue to penetrate and grow with the top drugs by sales and volume

- OptimizeRx provides digital solutions for 28% (by count) of the top 200 .
- Significant identified whitespace for OptimizeRx to continue to penetrate .



Optimize Rx


5 Solutions 4 Solutions 3 Solutions 2 Solutions 1 Solutions No Solutions

Strong Financial Momentum

Q1 2023 Results

\$13.0
Million
Revenue
(\$6.4)
Million
GAAP Net Loss
(\$1.6)
Million
Non-GAAP Net Loss

Annual Revenue Growth (\$millions)



Key Performance Indicators

Our footprint in the top 20 pharmaceutical manufacturers positions us well to compete and win our share of the largest category of addressable commercial spend

	Trailing Twelve Months March 31,	
KPIs	2023	2022
Average revenue per top 20 pharmaceutical manufacturer	\$2.0M	\$2.6M
% of top 20 pharmaceutical manufacturers that are customers	90%	90%
% of total revenue attributable to top 20 pharmaceutical manufacturers	58%	74%
Net revenue retention	86%	124%
Revenue per average full-time employee	\$605K	\$733K


Definition of Key Performance Indicators (KPIs)

• Top 20 pharmaceutical manufacturers: Top 20 pharmaceutical manufacturers are based on Fierce Pharma's "The top 20 pharma companies by 2022 revenue."

• Net revenue retention: Net revenue retention is a comparison of revenue generated from all customers in the previous period to total revenue generated from the same customers in the following year (i.e., excludes new customer relationships for the most recent year).

• Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM.

Key Takeaways



Thank you!

OptimizeRx Contact Ed Stelmakh, CFO/COO estelmakh@optimizerx.com

Media Relations Contact Kimberley Sirk, Media Relations ksirk@optimizerx.com

Investor Relations Contact Ashley Robinson LifeSci Advisors, LLC arr@lifesciadvisors.com



Andrew D'Silva, Senior Vice President of Corporate Finance




Andrew D'Silva has over a decade of equity research and capital markets experience, and most recently served as a senior healthcare research analyst at B. Riley Securities. Earlier in his career, he was a managing director and part of Merriman Capital's equity research team.

Andrew brings his deep experience in capital markets, and in-depth understanding of the healthcare technology sector to OptimizeRx where he is responsible for helping the Company with its strategic growth, and working alongside the commercial and financial teams in the design of capital allocation strategies to further drive growth.

Share Data and Key Financial Highlights

(NASDAQ:OPRX)

Stock Price (5/10/23)	\$14.28
52 Week Low-High	\$12.20 – \$30.82
Avg. Vol. (3-mo.)	252,118
Shares Outstanding	17.1M
Public Free Float (est.)	~95.0%
Institutional Holdings	65.8%
Insider Holdings	3.4%
Market Cap	\$244.6M
Enterprise Value	\$170.9M




Net Revenue ttm @ 3/31/23	\$61.7M
Gross Profit ttm	\$38.3M
GAAP Net Income ttm	(\$14.1)M
Non-GAAP Net Income ttm	\$4.9M
Cash and Cash Equivalents ¹	\$73.7M
Total Assets @ 3/31/23	\$131.7M
Total Debt @ 3/31/23	\$0.0M
Total Liabilities @ 3/31/23	\$7.7M
Full-time Employees	107

¹Includes short-term investments ttm = trailing twelve months ended March 31, 2023.

mrq = most recent quarter as of March 31, 2023.

Sources: Company, BigCharts.com and Yahoo!Finance.

For definition of non-GAAP Net Loss and reconciliation to GAAP, see end of this presentation.



Optimize **R***

21

Reconciliation of Non-GAAP to GAAP Financial Measures (Unaudited)

The Company defines non-GAAP net income as GAAP net income (loss) with an adjustment to add back depreciation, amortization, stock-based compensation, acquisition expenses, income or loss related to the fair value of contingent consideration, and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares outstanding on a diluted basis. The Company has provided non-GAAP financial measures to aid investors in better understanding its performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cash flow of the Company.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a Company's non-cash operating expenses, management believes that providing non-GAAP financial measures that exclude non-cash expenses allows for meaningful comparisons between the Company's core business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the Company's own core business operating results over different periods of time.

The Company's non-GAAP net income and non-GAAP EPS measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate such non-GAAP financial results differently. The Company's non-GAAP net income and non-GAAP EPS are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The Company does not consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.

The table, "Reconciliation of non-GAAP to GAAP Financial Measures," included below, provides a reconciliation of non-GAAP net income for the three and twelve months ended March 31, 2023.

For the Three Months Ended March 31. 2023 2022 \$ (6.397,714) \$ (3,761,098) Net loss Depreciation and amortization 463,933 471.539 Stock-based compensation 4.380.503 3,174,098 Acquisition expense 17,160 Non-GAAP net loss (1.553.278)(98.301)Non-GAAP net loss per share Diluted \$ (0.09) \$ (0.01)Weighted average shares outstanding: Diluted 17.094.676 17.878.068